- Home
- VHI vs PHVS Comparison
VHI vs PHVS Comparison
Compare VHI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VHI
- PHVS
- Stock Information
- Founded
- VHI 1932
- PHVS 2015
- Country
- VHI United States
- PHVS Switzerland
- Employees
- VHI N/A
- PHVS N/A
- Industry
- VHI Major Chemicals
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- VHI Industrials
- PHVS Health Care
- Exchange
- VHI Nasdaq
- PHVS Nasdaq
- Market Cap
- VHI 447.6M
- PHVS 980.3M
- IPO Year
- VHI N/A
- PHVS 2021
- Fundamental
- Price
- VHI $18.10
- PHVS $18.60
- Analyst Decision
- VHI Sell
- PHVS Buy
- Analyst Count
- VHI 1
- PHVS 6
- Target Price
- VHI $12.00
- PHVS $37.17
- AVG Volume (30 Days)
- VHI 25.1K
- PHVS 35.9K
- Earning Date
- VHI 08-07-2025
- PHVS 08-13-2025
- Dividend Yield
- VHI 1.77%
- PHVS N/A
- EPS Growth
- VHI 4465.30
- PHVS N/A
- EPS
- VHI 4.11
- PHVS N/A
- Revenue
- VHI $2,112,800,000.00
- PHVS N/A
- Revenue This Year
- VHI $22.20
- PHVS N/A
- Revenue Next Year
- VHI $7.66
- PHVS N/A
- P/E Ratio
- VHI $4.41
- PHVS N/A
- Revenue Growth
- VHI 7.82
- PHVS N/A
- 52 Week Low
- VHI $14.10
- PHVS $11.51
- 52 Week High
- VHI $41.75
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- VHI 67.06
- PHVS 60.00
- Support Level
- VHI $15.95
- PHVS $16.72
- Resistance Level
- VHI $18.70
- PHVS $17.53
- Average True Range (ATR)
- VHI 0.77
- PHVS 0.93
- MACD
- VHI 0.28
- PHVS 0.07
- Stochastic Oscillator
- VHI 82.56
- PHVS 92.86
About VHI Valhi Inc.
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.